Research programme: human cytomegalovirus infections therapeutics - AiCurisAlternative Names: AIC 813; HCMV therapeutics - AiCuris
Latest Information Update: 06 Sep 2016
At a glance
- Originator AiCuris
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cytomegalovirus infections
Most Recent Events
- 06 Sep 2016 The research programme is still in preclinical development for Cytomegalovirus infections (AiCuris pipeline, September 2016)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cytomegalovirus infections in Germany